Biotech: Page 2
-
Moderna vaccine sales surpass expectations as company looks to fall boosters
The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S. might shift from the federal government to private payers.
By Ned Pagliarulo • May 4, 2022 -
Regeneron tries to shake off fall in COVID drug sales with first quarter earnings
Partnerships and profit-sharing deals helped Regeneron overcome the sudden loss of U.S. revenue for its coronavirus antibody, which was withdrawn from the market as omicron spread.
By Kristin Jensen • May 4, 2022 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.TrendlineCell therapy
Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches.
By BioPharma Dive staff -
Spero to lay off 75% of workforce, change strategy after FDA challenges study results
Agency statisticians took a different view of the Phase 3 results the biotech was relying on to support approval of a new antibiotic, an announcement that triggered the sector's latest restructuring.
By Ben Fidler • May 4, 2022 -
Biogen CEO to step down as company pulls back from Alzheimer's drug
Michel Vounatsos, Biogen's CEO since 2017, will be replaced as the company "substantially" eliminates the commercial workforce around Aduhelm, which has generated paltry sales in the face of resistance from insurers and doctors.
By Jacob Bell • Updated May 3, 2022 -
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
A cancer biotech attracts another deep-pocketed partner in Gilead
Following rivals like Bristol Myers Squibb and Merck, Gilead has linked up with Dragonfly Therapeutics to develop new immunotherapies based on "natural killer cell engagers."
By Jacob Bell • May 2, 2022 -
AbbVie's first shot at Vertex misses, but it's not abandoning cystic fibrosis
Executives on Friday said that the company's three-drug therapy, a possible threat to Vertex's top-selling medicine Trikafta, didn't meet expectations in a key study. A new combination could start testing next year, however.
By Jacob Bell • April 29, 2022 -
After setbacks, a gene therapy company mulls a sale
Sio Gene Therapies, formerly known as Axovant, said it's focused on conserving cash, and has decided to significantly reduce its workforce and terminate licensing agreements on its last two pipeline programs.
By Jacob Bell • April 28, 2022 -
Two biotechs set out to end sector's IPO drought
HilleVax and Belite Bio could soon become the first biotechs to go public in almost two months, representing a key test of investors’ willingness to support emerging life sciences companies.
By Ben Fidler • April 27, 2022 -
Solid Bio joins slate of biotech layoffs, shedding 35% of its workforce
The company is the latest in a growing list of gene therapy developers to restructure and cut jobs during an industry-wide downturn.
By Jonathan Gardner • April 27, 2022 -
Undeterred by gene therapy's struggles, a startup launches into a downturn
Apertura Gene Therapy, a new company formed by Deerfield, is hoping a suite of next-generation tools will help it stand out at a time when this area of research has fallen out of favor with some public investors.
By Jacob Bell • April 26, 2022 -
Nektar begins sweeping layoffs after $2B Bristol Myers deal falls apart
Loss of the lucrative partnership has triggered a wide-ranging restructuring that will pare down Nektar’s workforce by about 70%.
By Jonathan Gardner • April 26, 2022 -
Black Diamond, yielding to competitors, scraps its top drug and cuts jobs
The fast progress of similar targeted cancer medicines led the company, which raised $201 million in an initial public offering just two years ago, to change direction and reduce its workforce by 30%.
By Ben Fidler • April 25, 2022 -
Seagen to expand, add jobs with new cancer drug factory
While some biotechs are restructuring amid a market downturn, SeaGen plans to add 200 positions through a large manufacturing plant that should be operational in 2024.
By Jacob Bell • April 21, 2022 -
Satellite Bio launches with new approach to bioengineering tissues
Backed by $110 million in venture funding, Satellite is led by Dave Lennon, formerly head of Novartis Gene Therapies.
By Ned Pagliarulo • April 20, 2022 -
Imara to reduce staff by 83% amid biotech shakeout
The planned job cuts were announced days after Imara — one of three spinouts from the drug accelerator Cydan Development — stopped development of its top medicine.
By Ben Fidler • April 18, 2022 -
Editas CEO to step down in latest executive change-up
A little more than a year after taking on the role, Jim Mullen is preparing to pass the torch to Gilmore O'Neill, who has served as the chief medical officer at Sarepta Therapeutics.
By Jacob Bell • April 14, 2022 -
ProQR to lay off 30% of staff following eye drug setback
In the near term at least, the biotech company is pinning hopes for its lead eye disease treatment on a new analysis of a recently failed study.
By Kristin Jensen • April 13, 2022 -
Versant-backed startup launches with plans to broaden cell therapy's reach
Cimeio Therapeutics, which emerged Wednesday with $50 million in funding, will use "shielding" technology to try to bring stem cell transplants and adoptive cell therapy to more patients.
By Ned Pagliarulo • April 13, 2022 -
UK bid to battle antibiotic resistance yields first subscription-style plan
Pfizer and Shionogi could receive 10 million pounds, or about $13 million, a year for new antibiotics. International participation might be needed to further spur development, however.
By Jonathan Gardner • April 12, 2022 -
AACR 2022: NK cell promise, more TIGIT questions and extending CAR-T's reach
This year's meeting on early cancer research featured promising study results from German biotechs BioNTech and Affimed as well as details from a "practice-changing" lung cancer trial.
By Ben Fidler , Ned Pagliarulo • April 11, 2022 -
Sponsored by Janssen Oncology
[Podcast] Breaking Down Barriers: How Bladder Cancer Innovations Benefit Patients and Treatments for Other Diseases
Recent breakthroughs in bladder cancer treatment are helping patients combat one major challenge to current options — the bladder permeability barrier. These treatments also have implications for other cancers and diseases. This podcast explains how.
By BioPharma Dive's studioID • April 11, 2022 -
Biotech startups face 'trickle-down effects' as sector's IPO drought endures
The slowdown has already forced many biotechs to wait longer to go public. There are early signs private financing deals may be flagging as well.
By Ben Fidler • April 11, 2022 -
Akebia to lay off 42% of workforce, suspend trials after FDA drug rejection
The layoffs come after safety concerns led the FDA to rebuff its anemia pill, similar to the agency's spurning of FibroGen's rival drug last year.
By Ben Fidler • April 7, 2022 -
Alnylam to wait longer for FDA verdict on latest RNA drug
The FDA has yet to sign off on a third-party packaging and labeling facility that Alnylam planned to help launch its drug, called vutrisiran, meaning an approval decision could come as late as mid-July.
By Jacob Bell • April 4, 2022 -
Vertex gets positive trial results for non-opioid painkiller in boost to pipeline
After several attempts at designing a drug for acute pain, Vertex has a candidate it's ready to take into late-stage testing following two successful Phase 2 studies.
By Ned Pagliarulo • March 31, 2022